Barclays PLC Purchases 126,562 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Barclays PLC raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 159.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 206,108 shares of the biopharmaceutical company's stock after acquiring an additional 126,562 shares during the period. Barclays PLC owned approximately 0.22% of Ultragenyx Pharmaceutical worth $8,671,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $35,000. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $42,000. Van ECK Associates Corp grew its holdings in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth about $83,000. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.45 on Friday, reaching $38.09. 575,372 shares of the company traded hands, compared to its average volume of 818,321. The firm has a market capitalization of $3.58 billion, a PE ratio of -6.01 and a beta of 0.61. The company has a 50 day moving average of $37.79 and a 200 day moving average of $43.68. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 967 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at $2,116,156.50. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Piper Sandler lowered their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. JPMorgan Chase & Co. lifted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.